RxDoctor Payments Data

Kimberly Hagar, MD

Family Medicine · Childress, TXNPI 1053721910

Payments from drug & device makers

$493in general payments, 2019–2025

Across 26 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$192
  • Novartis$89
  • Amgen$44
  • Astellas Pharma US Inc$34
  • Novo Nordisk$27
  • Biohaven Pharmaceuticals, Inc.$24
  • plus $84 from 6 others

What the payments were for

  • Food & beverage$493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$493 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$18,042
Medicare patients
139
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$67,996
JardianceEmpagliflozin28$33,923
EliquisApixaban26$26,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$24,156
TrulicityDulaglutide25$24,037
XareltoRivaroxaban21$20,902
Breo ElliptaFluticasone/Vilanterol34$16,471
MounjaroTirzepatide12$14,628
RybelsusSemaglutide11$10,540
MyrbetriqMirabegron17$10,497
Tresiba Flextouch U-100Insulin Degludec19$9,806
Fentanyl51$4,407
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$3,866
Humalog Kwikpen U-100Insulin Lispro23$3,613
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$27$78,53664 claims
GSKTrelegy Ellipta, Breo Ellipta$14$40,62650 claims
PfizerEliquis$12$26,08026 claims
Astellas Pharma US IncMyrbetriq$34$10,49717 claims
AbbVieSynthroid$192$74614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Childress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →